论文部分内容阅读
目的观察甘精胰岛素联合口服降糖药(OADs)治疗2型糖尿病的安全达标。方法选择OADs血糖控制不佳[糖化血糖蛋白(HbA1c)>7.5%)]的2型糖尿病患者22例,采用甘精胰岛素联合OADs治疗,观察用药后空腹血糖(FBG)和HbA1c的变化。结果治疗后1、2、3、4、8、12周的FBG水平均较治疗前显著降低(P<0.01);治疗后12周HbA1c较治疗前显著下降(P<0.01),治疗12周后所有患者HbA1c<6.5%;体重有轻微增加,差异无统计学意义;低血糖发生率低。结论甘精胰岛素能有效降低血糖,尤其对空腹血糖的作用大;不易出现低血糖,是一种较理想的作为基础胰岛素使用的药物。甘精胰岛素联合OADs治疗2型糖尿病可以安全达标。
Objective To observe the safety compliance of insulin glargine combined with oral hypoglycemic agents (OADs) in the treatment of type 2 diabetes mellitus. Methods 22 patients with type 2 diabetes mellitus (OGDG) whose OGs were poorly controlled by OADs (HbA1c> 7.5%) were treated with insulin glargine and OADs to observe the changes of fasting blood glucose (FBG) and HbA1c after treatment. Results The levels of FBG at 1, 2, 3, 4, 8 and 12 weeks after treatment were significantly lower than those before treatment (P <0.01). HbA1c was significantly decreased 12 weeks after treatment (P <0.01) All patients had a HbA1c <6.5%; body weight increased slightly, with no significant difference; low incidence of hypoglycemia. Conclusion Glargine can effectively lower blood glucose, especially for fasting blood glucose; it is not prone to hypoglycemia and is an ideal drug for basal insulin use. Glargine and OADs in combination with type 2 diabetes can be safely achieved.